AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.
Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.
1705 articles about AbbVie
-
7 Top Companies Hiring Regulatory Jobs
3/14/2024
Looking for regulatory jobs in the biopharma industry? Check out the BioSpace list of seven top companies hiring for these critical roles. -
AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference
3/7/2024
AbbVie (NYSE: ABBV) will participate in the Barclays 26th Annual Global Healthcare Conference on Thursday, March 14, 2024.
-
AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios
3/6/2024
AbbVie and Allergan Aesthetics, an AbbVie company, today announced they will present 29 abstracts, including three late-breaking presentations, during the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12, in San Diego, California.
-
Despite the changing landscape in biopharma, many companies are still recruiting. If you’re looking to make a career change, here are 12 biopharma companies hiring on BioSpace now.
-
JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval
3/5/2024
Allergan Aesthetics, an AbbVie company, announced the U.S. FDA approval of JUVÉDERM® VOLUMA® XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21.
-
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
2/28/2024
AbbVie Inc. and OSE Immunotherapeutics SA, a clinical-stage immunotherapy company, announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.
-
AbbVie continued its dealmaking spree Wednesday by partnering with OSE Immunotherapeutics to develop its early-stage, first-in-class antibody for chronic and severe inflammation.
-
U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
2/27/2024
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp, a subcutaneously administered T-cell engaging bispecific antibody for the treatment of adult relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy.
-
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
2/27/2024
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY ® ) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma.
-
AbbVie to Present at the TD Cowen 44th Annual Health Care Conference
2/27/2024
AbbVie (NYSE: ABBV) will participate in the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024.
-
Thanks to the success of outgoing CEO Richard Gonzalez, biopharma executives will be studying for years to come how AbbVie navigated the decline of blockbuster Humira.
-
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
2/22/2024
AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.
-
After a slow start to 2023 in an uncertain economic climate, biopharma mergers and acquisitions are on the rise.
-
President and COO Robert Michael will take over Richard Gonzalez’s CEO duties, AbbVie announced Tuesday. Gonzalez will become executive chairman of the board of directors.
-
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
2/20/2024
AbbVie (NYSE: ABBV) today announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez.
-
AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn's and Colitis Organisation (ECCO)
2/19/2024
AbbVie (NYSE: ABBV) announced that 17 AbbVie-sponsored abstracts, including new data from its inflammatory bowel disease (IBD) portfolio, have been accepted for presentation at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.
-
AbbVie Declares Quarterly Dividend - February 15, 2024
2/15/2024
The board of directors of AbbVie Inc. declared a quarterly cash dividend of $1.55 per share.
-
AbbVie Completes Acquisition of ImmunoGen
2/12/2024
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of ImmunoGen (NASDAQ: IMGN).
-
Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases
2/6/2024
The Calibr-Skaggs Institute for Innovative Medicines, the nonprofit drug development division of Scripps Research, announced today that AbbVie (NYSE: ABBV) has expanded its collaboration to further explore Calibr-Skaggs' switchable CAR-T (sCAR-T) platform in solid tumor indications and autoimmune diseases.
-
With one disease-modifying therapy already reaching patients and another expected to soon, several biopharma companies anticipate key data for novel assets in the coming 12 months.